Regeneron Pharmaceuticals REGN Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's free cash flow?
- Regeneron Pharmaceuticals (REGN) reported free cash flow of $848.3M in Q1 2026.
- How has Regeneron Pharmaceuticals's free cash flow changed year-over-year?
- Regeneron Pharmaceuticals's free cash flow increased by 4.0% year-over-year, from $815.8M to $848.3M.
- What is the long-term trend for Regeneron Pharmaceuticals's free cash flow?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's free cash flow has grown at a -11.1% compound annual growth rate (CAGR), from $6.53B to $4.08B.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.